PLP-3 R
Triple agonist, still in Phase 3, not approved anywhere. The Phase 2 results were striking, which is exactly why caution matters.
In trials, not approved
| What it is | A triple agonist at the GLP-1, GIP and glucagon receptors, in development by Eli Lilly. |
|---|---|
| How it is thought to work | Adds glucagon receptor activity to the dual mechanism, which increases energy expenditure as well as reducing intake. |
| What the evidence actually shows | Phase 2 results published in the New England Journal of Medicine in 2023 showed large weight reductions over 48 weeks. Phase 3 trials are ongoing. No regulator has reviewed a complete submission. |
| Regulatory status | Not approved by the FDA or any other major regulator as of 1 October 2026. It remains an investigational drug in Phase 3 trials. |
| Dosing | There is no approved dose, because there is no approved product. The published Phase 2 trial escalated weekly doses up to 12 mg under close medical supervision with regular monitoring — that is a trial protocol with safety monitoring attached, not a usage guide. |
| In the catalog as |
Risks and cautions
- Dose-dependent gastrointestinal effects were the most common adverse events in Phase 2.
- Increases in heart rate were observed.
- Because Phase 3 is not complete, the full safety profile is by definition not yet known. That is what Phase 3 is for.
- Glucagon receptor activity adds metabolic effects that the GLP-1-only drugs do not have.
Why this matters specifically with EDS
All the gastric emptying cautions from the other two apply. On top of that, the observed heart rate increase deserves specific thought if you have POTS or any form of dysautonomia, where resting and standing heart rate is already the problem.
Before you act on any of this
This page describes what is known and what is not. It is not a recommendation to use anything, and it is not a protocol. Compounds listed as research chemicals are not approved medicines and are not sold for human use. Talk to a doctor who knows your history.